International guidelines for clinical diagnosis and treatment of Hirayama disease

复旦大学附属华山医院骨科,北京大学第三医院骨科,《中华骨科杂志》编辑部,姜建元,孙宇,胡永成
DOI: https://doi.org/10.3760/cma.j.issn.0253-2352.2019.08.002
2019-01-01
Abstract:Hirayama disease(HD)is a clinical disease characterized by puberty onset and limited muscle atrophy of the upper extremities.HD usually occurs in Asian males at the peak of growing development.Because of concealed progress of HD and its early clinical manifestations similar to motor neuron disease,the early diagnosis rate of HD is low,therefore,the patients with HD often cannot get timely and effective treatment.Although the prognosis of HD is obviously better than that of motor neuron disease,the lack of timely and effective treatment will cause severe muscle atrophy.Therefore,HD needs a guideline with sufficient theoretical basis,wide coverage,strong technical guidance and suitable for patients with HD.Based on these reasons,forty-seven experts from 6 countries and 7 professional fields around the world were organized by Department of Orthopeadics,Huashan Hospital,Fudan University;Department of Orthopaedics,Peking University Third Hospital;and Editorial Office of Chinese Journal of Orthopaedics;and they discussed and formulated the guidelines that systematically introduces the diagnosis and treatment measures of HD from the aspects of epidemiology,clinical manifestation,imaging and electrophysiological characteristics,differential diagnosis,clinical classification,conservative and surgical treatment,and curative effect evaluation,in order to standardize and promote the diagnosis and treatment of HD and improve the early diagnosis and effective intervention of HD.
What problem does this paper attempt to address?